AKAN
Price
$0.69Alerts
Change
-$0.04 (-5.48%)
Updated
Nov 12, 02:43 PM (EDT)
Capitalization
454.36K
Intraday BUY SELL Signals
CABR
Price
$0.80Alerts
Change
-$0.06 (-6.98%)
Updated
Nov 12, 03:06 PM (EDT)
Capitalization
10.58M
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AKAN vs CABR

AKAN vs CABR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AKAN vs. CABR commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKAN is a StrongBuy and CABR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AKAN with price predictions
Nov 11, 2026

AKAN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for AKAN turned positive on October 21, 2026. Looking at past instances where AKAN's MACD turned positive, the stock continued to rise in 36 of 38 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +7.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKAN advanced for three days, in 140 of 170 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

AKAN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKAN as a result. In 82 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKAN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for AKAN entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.138) is normal, around the industry mean (6.379). P/E Ratio (0.001) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.032) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. AKAN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKAN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for CABR with price predictions
Nov 11, 2026

Momentum Indicator for CABR turns negative, indicating new downward trend

CABR saw its Momentum Indicator move below the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator turned negative. In 26 of the 26 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CABR turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In 11 of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

CABR moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 17 of 17 cases where CABR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

Following a +13.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABR advanced for three days, in 54 of 57 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

CABR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. CABR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.906) is normal, around the industry mean (6.379). P/E Ratio (-1.308) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. CABR's P/S Ratio (10000.000) is very high in comparison to the industry average of (183.387).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
AKANCABR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 17 days ago
82%
Bullish Trend about 1 month ago
90%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (AKAN: $0.73 vs. CABR: $0.86)
Brand notoriety: AKAN and CABR are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AKAN: 23% vs. CABR: 70%
Market capitalization -- AKAN: $454.36K vs. CABR: $10.58M
AKAN [@Pharmaceuticals: Generic] is valued at $454.36K. CABR’s [@Pharmaceuticals: Generic] market capitalization is $10.58M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKAN’s FA Score shows that 1 FA rating(s) are green while CABR’s FA Score has 1 green FA rating(s).

  • AKAN’s FA Score: 1 green, 4 red.
  • CABR’s FA Score: 1 green, 4 red.
According to our system of comparison, both AKAN and CABR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKAN’s TA Score shows that 3 TA indicator(s) are bullish while CABR’s TA Score has 3 bullish TA indicator(s).

  • AKAN’s TA Score: 3 bullish, 3 bearish.
  • CABR’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, AKAN is a better buy in the short-term than CABR.

Price Growth

AKAN (@Pharmaceuticals: Generic) experienced а -26.57% price change this week, while CABR (@Pharmaceuticals: Generic) price change was -4.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.13%. For the same industry, the average monthly price growth was -6.49%, and the average quarterly price growth was +10.54%.

Reported Earning Dates

CABR is expected to report earnings on Nov 13, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.13% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

AKAN and

Correlation & Price change

A.I.dvisor tells us that AKAN and CGC have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKAN and CGC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKAN
1D Price
Change %
AKAN100%
-0.53%
CGC - AKAN
30%
Poorly correlated
+2.13%
OGI - AKAN
25%
Poorly correlated
+0.15%
SNOA - AKAN
25%
Poorly correlated
+8.77%
SNDL - AKAN
24%
Poorly correlated
+2.16%
ACB - AKAN
22%
Poorly correlated
-1.17%
More

CABR and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABR has been loosely correlated with TLRY. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CABR jumps, then TLRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABR
1D Price
Change %
CABR100%
-8.94%
TLRY - CABR
38%
Loosely correlated
-1.51%
BFRI - CABR
22%
Poorly correlated
+1.02%
AKAN - CABR
6%
Poorly correlated
-0.53%
TEVA - CABR
6%
Poorly correlated
+1.98%
CTOR - CABR
5%
Poorly correlated
-0.71%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ROIV41.850.66
+1.60%
Roivant Sciences Ltd
MITK18.740.21
+1.13%
Mitek Systems
STRO10.260.09
+0.88%
Sutro Biopharma Inc.
DUKR2.910.01
+0.34%
Duke Robotics Corp.
SMG65.04-0.09
-0.14%
Scotts Miracle-Gro Company (The)